KBC Group
AGIO icon

KBC Group’s Agios Pharmaceuticals AGIO Stock Holding History

KBC Group’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$69K Hold
2,073
– – ﹤0.01% 1606
2026
Q2 		$77K Hold
2,073
– – ﹤0.01% 1544
2026
Q1 		$70K Sell
2,073
-947
-31% -$26.8K ﹤0.01% 1504
2025
Q4 		$82K Buy
3,020
+1,269
+72% +$44.5K ﹤0.01% 1408
2025
Q3 		$70K Hold
1,751
– – ﹤0.01% 1481
2025
Q2 		$58K Sell
1,751
-864
-33% -$26.2K ﹤0.01% 1530
2025
Q1 		$77K Hold
2,615
– – ﹤0.01% 1615
2024
Q4 		$86K Buy
2,615
+611
+30% +$28.7K ﹤0.01% 1641
2024
Q3 		$89K Hold
2,004
– – ﹤0.01% 1357
2024
Q2 		$86K Buy
+2,004
New +$72.3K ﹤0.01% 1255

Other funds holding AGIO

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $13.7B AUM 40.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
SCS Capital Management
SCS Capital Management Boston, Massachusetts $11.2B AUM 12.39% 1-Year Est. Return
Panagora Asset Management
Panagora Asset Management Boston, Massachusetts $33.2B AUM 43.67% 1-Year Est. Return

KBC Group's AGIO Position: Q3 2026 in Review

KBC Group held its Agios Pharmaceuticals (AGIO) position steady in Q3 2026 at 2,073 shares worth $69K. The position accounts for ﹤0.01% of the portfolio, ranked #1606.

KBC Group first reported a position in AGIO in Q2 2024 and has held it in 10 quarters since. The position peaked at $89K in Q3 2024. 139 funds tracked by Wall St. Rank hold AGIO as of Q3 2026.

  • KBC Group held 2,073 shares of Agios Pharmaceuticals worth $69K as of Q3 2026.
  • KBC Group left its Agios Pharmaceuticals share count unchanged in Q3 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1606 holding.
  • KBC Group first reported a position in Agios Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • KBC Group's Agios Pharmaceuticals position peaked at $89K in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.